Sebela Pharmaceuticals

Sebela Pharmaceuticals is a private, commercial-stage biopharmaceutical company founded in 2014 and headquartered in Braintree, Massachusetts. The company operates with a dual focus: maintaining a leading position in the gastroenterology market through its affiliate Braintree and driving innovation in women's health via its Sebela Women's Health division. Its near-term value drivers include the FDA review of tegoprazan for GERD and the recent licensing of its hormone-free IUD, MIUDELLA®, to Organon, while its pipeline suggests a commitment to sustained growth in its core therapeutic areas.

Integrated development and commercial capability focused on small molecule drugs and medical devices for GI disorders and women's health conditions.

In GI, Sebela's tegoprazan will compete against generic proton pump inhibitors and other acid-suppressing therapies. In women's health, its IUD programs face competition from dominant players like Bayer (Mirena, Kyleena) and CooperSurgical (Paragard), making effective differentiation and commercial strategy critical.